Showing 2121-2130 of 5789 results for "".
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and l
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl
- Evolus Acquires Exclusive US Distributor Rights to Evolysse Line of Dermal Fillershttps://practicaldermatology.com/news/evolus-acquires-exclusive-us-distributor-rights-to-evolysse-line-of-dermal-fillers/2461710/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiativehttps://practicaldermatology.com/news/stony-brook-university-hospital-and-the-mollie-biggane-melanoma-foundation-promote-skin-cancer-prevention-through-new-inpatient-initiative/2461709/Stony Brook University Hospital (SBUH) and the Mollie Biggane Melanoma Foundation announce a collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program, according to a news release. Historicall
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin
- U.S. FDA Grants Breakthrough Therapy Designation to Spevigo for the prevention of GPP Flareshttps://practicaldermatology.com/news/us-fda-grants-breakthrough-therapy-designation-to-spevigo-for-the-prevention-of-gpp-flares-1/2461694/The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Spevigo for the prevention of generalized pustular psoriasis (GPP) flares, Boehringer Ingelheim reports. This designation follows the Center for Drug Evaluation (CDE) of China National Medic